Antibody–drug conjugates (ADCs) are biopharmaceuticals produced by chemically linking
small molecules (payloads) to antibodies that possess specific affinity for the target cell. The …

Over the last decade, the biopharmaceutical market has witnessed a new wave of
development in antibody–drug conjugates (ADCs) due to their high efficacy in cancer …

Antibody–drug conjugates (ADCs) have become a major class of oncology
biopharmaceuticals. Traditional ADCs have a stochastic distribution of cytotoxic drugs …

The production of antibody-drug conjugates (ADCs) has been in great demand in the field of
cancer therapeutics. Although cysteine-based conjugation is the most common and well …

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics in which a potent
small molecule is linked to an antibody. ADCs are highly complex and structurally …

Antibody–drug conjugates (ADCs) are monoclonal antibodies with covalently bound
cytotoxic drugs. They are designed to target tumor antigens selectively and offer the hope of …

Background: Antibody–drug conjugates (ADCs) are a new class of cancer therapeutics that
deliver potent cytotoxins specifically to tumors to minimize systemic toxicity. However …

Antibody-drug conjugates (ADCs) are a unique class of biotherapeutics of inherent
heterogeneity and correspondingly complex absorption, distribution, metabolism, and …

Currently, the most bioanalytically challenging drugs are antibody–drug conjugates (ADCs),
constructs comprising a monoclonal antibody and a cytotoxic drug connected by a linker …

Antibody–drug conjugates (ADCs) require multiple assays for analytical and bioanalytical
characterization due to their heterogeneous and dynamic nature. These assays can help …